The Efficacy of Intravenous Immunoglobulin for the Treatment of Bronchopulmonary Dysplasia

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

It is intended to examine the efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable 1\ 2 times if necessary (5 days after the last infusion).

Eligibility
Participation Requirements
Sex: All
Maximum Age: 2 months
Healthy Volunteers: f
View:

• Gestational age between 25 weeks and 31 weeks + 6 days

• Admission within 24 hours after birth.

• Clinical symptoms and chest X-ray results show a highly suspicion of BPD.Clinical symptoms develop in several days or weeks after birth, including respiratory symptoms and signs such as shortness of breath, cyanosis or pulmonary rales, intermittent hypoxic attacks, and chronic oxygen dependence (increased oxygen concentration and assisted ventilation) .One of the following signs present in chest X-ray: lung texture thickening or ground glass opacity in early stage, diffuse lung texture blurred, lung hyperinflation, shadow of linear density increased, and shadow of triangular density increased under the pleura.

Locations
Other Locations
China
International Peace Maternity and Child Health Hospital
RECRUITING
Shanghai
Contact Information
Primary
Fu Xuemei
fxmzj2004@163.com
+86 18017313931
Backup
Li Dan
lidan910327@126.com
+86 18814100771
Time Frame
Start Date: 2025-04
Estimated Completion Date: 2027-12
Participants
Target number of participants: 10
Treatments
Experimental: IVIG
Related Therapeutic Areas
Sponsors
Leads: International Peace Maternity and Child Health Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials